AVE 0.00% 0.2¢ avecho biotechnology limited

Mylan arbitration, page-294

  1. 4,171 Posts.
    lightbulb Created with Sketch. 68
    And what do you think poh has to offer a partner ? Tpm offers no evidence of superiority as a permeator or solubizer compared to product readily avaible 'off the shelf'
    Pharma curiosity has always been exstrapolated into a potential deal as mak ' illustrates
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.